Spots Global Cancer Trial Database for TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
Official Title: A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors
Study ID: NCT04695327
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.
Detailed Description: This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 as monotherapy in advanced solid tumor patients. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin 2. The trial includes 2 healthcare centers in Helsinki (Finland). Patients with different indications are expected to be treated in the trial.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Helsinki University Hospital, Helsinki, Uusima, Finland
Docrates Cancer Center, Helsinki, Uusima, Finland
Contact Details
Name: Katriina Peltola, MD, PhD
Affiliation: Helsinki University Central Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Tuomo Alanko, MD, PhD
Affiliation: Docrates Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
